Le Lézard
Classified in: Health
Subject: ATY

Hagens Berman Reminds AbbVie (NYSE: ABBV) Investors of Ongoing Investigation of AbbVie's Humira Sales Practices


SAN FRANCISCO, Nov. 9, 2018 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP reminds investors in AbbVie Inc. (NYSE: ABBV) of the Firm's ongoing investigation of AbbVie's Humira sales practices.  If you purchased or otherwise acquired AbbVie securities between October 25, 2013 and September 18, 2018 and continue to hold shares contact Hagens Berman Sobol Shapiro LLP.  For more information visit:

https://www.hbsslaw.com/cases/ABBV

Hagens Berman Sobol Shapiro LLP

or contact Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000 or emailing

[email protected].

On September 18, 2018, Bloomberg reported California's insurance regulator is suing AbbVie, alleging that the Company gave illegal kickbacks to health-care providers in order to keep patients on its blockbuster rheumatoid arthritis drug Humira.

The California Department of Insurance accuses Abbvie of engaging "in a far-reaching scheme including both classic kickbacks ? cash, meals, drinks, gifts, trips, and patient referrals ? and more sophisticated ones ? free and valuable professional goods and services to physicians to induce and reward Humira prescriptions."

This news drove the price of AbbVie shares down $2.76 to close at $92.61 on September 18, 2018.

"We're focused on investors' losses and whether AbbVie's senior management and its directors knew of the facts supporting accusations by the California Department of Insurance," said Hagens Berman partner Reed Kathrein.

Whistleblowers:  Persons with non-public information regarding ABBV should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.  Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.  For more information, call Reed Kathrein at 510-725-3000 or email [email protected].

About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 80+ attorneys in 10 offices across the country.  The Firm represents investors, whistleblowers, workers and consumers in complex litigation.  More about the firm and its successes can be found at www.hbsslaw.com.  For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:
Reed Kathrein, 510-725-3000

 

SOURCE Hagens Berman Sobol Shapiro LLP


These press releases may also interest you

at 18:24
The scheduled merits hearing dates, April 26 and 29, 2024, in the above-named matter will proceed by videoconference. On April 26, 2024, the hearing will commence 11:15 a.m. Members of the public may observe the hearing by videoconference, by...

at 17:55
Valeo Pharma Inc. ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced the results of the matters submitted to shareholders at its annual meeting of shareholders held on April 25, 2024 (the "Meeting")....

at 17:43
Community Healthcare Trust Incorporated today announced that its Board of Directors has increased its common stock cash dividend for the quarter ended March 31, 2024. This dividend, in the amount of $0.46 per share, is payable on May 24, 2024 to...

at 17:31
DelveInsight's Urine Output Monitoring Systems Market Insights report provides the current and forecast market analysis, individual leading urine output monitoring systems companies' market...

at 17:00
Enghouse Video, a global leader in cutting-edge video technology solutions, today announced its partnership with SONIFI Health, enhancing virtual care in hospital settings. SONIFI Health is a leading U.S. healthcare technology company based in Sioux...

at 17:00
A record 3,618 graduating students and physicians matched to residency training programs in Canada in this year's R-1 Main Residency Match (R-1 match), the Canadian Resident Matching Service (CaRMS) announced today....



News published on and distributed by: